Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-11-09
DOI
10.1007/s00262-018-2248-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunological effects of everolimus in patients with metastatic renal cell cancer
- (2017) Charlotte M Huijts et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity
- (2016) Laurent Beziaud et al. CANCER RESEARCH
- Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells
- (2016) Charlotte M. Huijts et al. CLINICAL IMMUNOLOGY
- Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
- (2016) Holger Moch et al. EUROPEAN UROLOGY
- Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
- (2016) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib Approved for Renal Cell Carcinoma
- (2016) Cancer Discovery
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis
- (2014) Sarah Dimeloe et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Human CD4+CD25+ Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response
- (2013) Daniel Heylmann et al. PLoS One
- Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide
- (2013) C. G. Kanakry et al. Science Translational Medicine
- Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials
- (2011) Chris Coppin et al. BJU INTERNATIONAL
- Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
- (2011) Charlotte M Huijts et al. BMC CANCER
- Sunitinib and other targeted therapies for renal cell carcinoma
- (2011) T Powles et al. BRITISH JOURNAL OF CANCER
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Selective Depletion of CD4+CD25+Foxp3+Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP Levels
- (2010) Jie Zhao et al. CANCER RESEARCH
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment
- (2009) Greg M. Delgoffe et al. IMMUNITY
- Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response
- (2009) Nan Soon Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- The multiple facets of mTOR in immunity
- (2009) Thomas Weichhart et al. TRENDS IN IMMUNOLOGY
- The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma
- (2008) Jin F. Li et al. BJU INTERNATIONAL
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+cells
- (2008) Sokol Haxhinasto et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started